Regional differences in the global burden of age-related macular degeneration

[11] Li Y(2018)Global, regional and national incidence, prevalence, and years lived with disability for 354 diseases and injuries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 1789-1762

[12] Xu L(2018)Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of Disease study 2017 Lancet 392 1859-567

[13] Jonas JB(1997)Learning and understanding the Kruskal-Wallis one-way analysis-of-variance-by-ranks test for differences among three or more independent groups Phys Ther 77 1755-1641

[14] Yang H(2005)Anti-macular degeneration agents Ophthalmol Clin N Am 18 561-1411

[15] Ma Y(2014)Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Br J Ophthalmol 98 1636-2309

[16] Li J(2012)Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 1399-271

[17] Li Y(2013)Ranibizumab versus Bevacizumab for Neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial Ophthalmology 120 2300-1267

[18] Xu L(2013)A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration Br J Ophthalmol 97 266-1398

[19] Wang YX(2013)Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 1258-1908

[20] You QS(2012)Ranibizumab and Bevacizumab for treatment of Neovascular age-related macular degeneration: 2-year results Ophthalmology 119 1388-2232

[11] Li Y(2018)Global, regional and national incidence, prevalence, and years lived with disability for 354 diseases and injuries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 1789-1762

[12] Xu L(2018)Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of Disease study 2017 Lancet 392 1859-567

[13] Jonas JB(1997)Learning and understanding the Kruskal-Wallis one-way analysis-of-variance-by-ranks test for differences among three or more independent groups Phys Ther 77 1755-1641

[14] Yang H(2005)Anti-macular degeneration agents Ophthalmol Clin N Am 18 561-1411

[15] Ma Y(2014)Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Br J Ophthalmol 98 1636-2309

[16] Li J(2012)Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 1399-271

[17] Li Y(2013)Ranibizumab versus Bevacizumab for Neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial Ophthalmology 120 2300-1267

[18] Xu L(2013)A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration Br J Ophthalmol 97 266-1398

[19] Wang YX(2013)Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 1258-1908

[20] You QS(2012)Ranibizumab and Bevacizumab for treatment of Neovascular age-related macular degeneration: 2-year results Ophthalmology 119 1388-2232